Quality control of protein crystal suspensions using microflow imaging and flow cytometry.

Protein crystallization is an attractive method for protein processing and formulation. However, minor changes in the crystallization setup can lead to changes in the crystal structure or the formation of amorphous protein aggregates, which affect the product quality. Only few analytical tools for qualitative and quantitative differentiation between protein crystals and amorphous protein exist. Electron microscopy requires expensive instrumentation, demanding sample preparation, and challenging image analysis. Therefore, there is a need to establish other analytical techniques. It was the aim of this study to investigate the capability of light obscuration (LO), microflow imaging (MFI), and flow cytometry (FC) in differentiating the amorphous and crystalline states of insulin as a relevant model. Qualitative discrimination of the two populations based on the particle size was possible using LO. Quantitative determination of amorphous protein and crystals by MFI was challenging due to overlapping size distributions. This problem was overcome by particle analysis based on the mean light intensity. Additionally, FC was applied as a new method for the determination of the quality and quantity of amorphous protein by differences in the light scattering. Our results show the potential of MFI and FC for rapid high throughput screening of crystallization conditions and product quality.

[1]  Roman Mathaes,et al.  Application of different analytical methods for the characterization of non-spherical micro- and nanoparticles. , 2013, International journal of pharmaceutics.

[2]  Henryk Mach,et al.  The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. , 2011, Journal of pharmaceutical sciences.

[3]  Theodore W Randolph,et al.  Flow cytometry: a promising technique for the study of silicone oil-induced particulate formation in protein formulations. , 2011, Analytical biochemistry.

[4]  S. Singh,et al.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.

[5]  M. Groves,et al.  A method for the general identification of protein crystals in crystallization experiments using a noncovalent fluorescent dye. , 2007, Acta crystallographica. Section D, Biological crystallography.

[6]  Alexander McPherson,et al.  Introduction to protein crystallization. , 2004, Methods.

[7]  A. Margolin,et al.  Injectable controlled release formulations incorporating protein crystals. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[8]  A. Margolin,et al.  Protein crystals for the delivery of biopharmaceuticals , 2004, Expert opinion on biological therapy.

[9]  Sergey Pechenov,et al.  Crystalline monoclonal antibodies for subcutaneous delivery , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Merkle,et al.  Diamonds in the rough: protein crystals from a formulation perspective. , 2001 .

[11]  B. Shenoy,et al.  Stability of crystalline proteins. , 2001, Biotechnology and bioengineering.

[12]  J. Vermant,et al.  Rheooptical determination of aspect ratio and polydispersity of nonspherical particles , 2001 .

[13]  S. Frokjaer,et al.  Pharmaceutical Formulation Development Of Peptides And Proteins , 2009 .